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Abstract The conduct of clinical trials in colorectal cancer has
historically relied upon endpoints such as disease-free (DFS) or
overall survival (OS). While ideal, these endpoints require long-
term follow-up, thus contributing to a slow pace of scientific
progress in clinical research. Identification of short-term end-
points to serve as surrogates for DFS and OSwould enable more
rapid determination of success or failure of an experimental in-
tervention and thus facilitate more scientific discovery and prog-
ress leading to clinical practice improvements. In rectal cancer
clinical trials, there have been few validated alternatives to DFS
and OS, including pathologic complete response (ypCR). The
neoadjuvant rectal (NAR) score was developed as a composite
short-term endpoint for clinical trials involving neoadjuvant ther-
apy for rectal cancer. The NAR score is based upon variables
routinely collected and available to clinical investigators during
the conduct of prospective studies. Based upon two independent
validation datasets, the NAR score predicts OS in rectal cancer
clinical trials better than ypCR. While final dataset validation is
ongoing, the NAR score offers an opportunity to incorporate a
novel surrogate endpoint into early phase rectal cancer clinical
trials.
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Introduction
Colorectal cancer (CRC) represents a highly prevalent but
treatable cancer. It is estimated that in 2015, there will be
132,700 new cases of CRC and 49,700 deaths from CRC in
the USA alone, accounting for it as the second leading cause
of cancer death [1]. The impact of an effective national screen-
ing program has been well defined [2•]. With screening com-
pliance improving, rates for new colon and rectum cancer
cases have been falling on average by approximately 3 % each
year over the last 10 years, but death rates have not changed
significantly over 2002–2012 [1]. Rectal cancer, also referred
to as a distal large bowel adenocarcinoma within 12–15 cm
from the anal verge, represents a subset of colorectal cancer
cases. For rectal cancer in the USA, there will be 39,610 new
cases in 2015 (male 23,200; female 16,410) representing near-
ly 1/3 of the total CRC cases [3].
Despite similar molecular and genetic profiles, rectal cancer
is treated differently from colon cancer in several important ways
[4••]. First, because of the pelvic anatomy and risk for close
surgical margins, rectal cancer management must include con-
sideration for local disease control. This is optimized by
performing total mesorectal excision (TME) and perioperative
chemoradiotherapy (CRT) [5]. Second, patients with low lying
rectal cancer are at risk for loss of sphincter function, requiring
permanent colostomy or suffer from fecal incontinence. Finally,
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risk stratification and management of rectal cancer requires mul-
tidisciplinary staging and care coordination including pelvic
magnetic resonance imaging (MRI) or endoscopic ultrasound
(EUS). Non-operative treatment decisions are made without
the benefit of pathologic staging since surgical resection is typ-
ically delayed until after neoadjuvant therapy.
Improvements in rectal cancer patient care have come as
the result of clinical trials testing new treatments and validat-
ing hypotheses. These pragmatic trials have provided signifi-
cant improvements in disease staging, local disease control,
patient survival, quality of life, and sphincter preservation [6].
As a result of several recent pivotal trials, there has been a
paradigm shift to include fluoropyrimidine-based CRT in the
neoadjuvant setting [7••, 8, 9••]. Consequently, there is a tre-
mendous desire to use the initial clinical and pathologic fea-
tures or the in vivo treatment effect as a surrogate for longer
term outcomes, both for individual patients and also as a val-
idated endpoint for the next generation of clinical trials.
Identifying a valid surrogate short-term endpoint would allow
determination of treatment efficacy in clinical trials in a
shorter period of time, resolving hypotheses and allowing
clinical progress to be made in more rapid fashion. Here, we
will focus on surrogate endpoints in rectal cancer clinical trials
with a newly validated surrogate, the neoadjuvant rectal
(NAR) score.
Surrogate Endpoints
The idea of using a surrogate endpoint (one that occurs earlier
or is more easily attainable) in lieu of a final (or true) endpoint
is not a new concept in clinical trial design [10]. Guidelines,
considerations, and limitations for establishing surrogate end-
points in clinical trials have been proposed by the National
Institutes of Health [11]. A surrogate endpoint requires two-
step validation through randomized controlled clinical trials to
ensure that (1) it correlates with the true endpoint (aka indi-
vidual level association) and (2) the effects of treatments that
impact the surrogate and true endpoints correlate (aka trial
level association) [12].
As previously stated, locoregional relapse was initially a
primary form of treatment failure in this disease. However,
with the introduction of TME and radiotherapy, local failure
is far exceeded by systemic metastatic development. The latter
significantly influences disease-free (DFS) and overall surviv-
al (OS). As such, these two benchmarks have been the primary
endpoints of most major rectal cancer clinical trials in the past
three decades [13, 14]. The prolongation of survival as a pri-
mary goal of new therapeutic interventions in rectal cancer is
laudable, but complicated by several highly effective agents in
the metastatic setting, improved supportive care, and opportu-
nities for salvage surgical resection or ablation of
oligometastatic disease. Thus, the duration of patient follow-
up from completion of rectal cancer treatment intervention
until death, as a primary endpoint, can take perhaps 3 to 5 years
longer than the original conduct of the entire clinical trial
itself. Although slightly shorter in time as an endpoint, the
same is true for DFS. In addition to the two-step validation
described above, an ideal surrogate endpoint would be
achieved at or near the completion of the clinical trial inter-
vention, be highly reproducible across different clinical trial
study designs and interventions, and be accomplished without
added complexity or cost to the patient or the clinical trial
design while correlating with the true endpoints of DFS and
OS (Table 1).
With the widespread use of TME, pathologic standardiza-
tion has become increasingly critical for accurate assessment
of nodal involvement, margin status, and pathologic staging.
While sentinel nodes and clinical responses have proved
largely to be poorly representative of systemic disease, histo-
pathology assessments have become critically important [15,
16]. However, the histopathologic assessment of the tumor
specimen (and thus any associated variable desired as a surro-
gate endpoint) is highly dependent upon the quality of the
pathologist review [17]. For local risk of recurrence, it was
verified that the circumferential radial margin status serves as
a highly valuable surrogate endpoint, even in the era of TME
[18, 19]. Attempts to identify a surrogate endpoint for DFS
and OS have proved more challenging. However, the intro-
duction of neoadjuvant CRT has offered the opportunity to
assess the degree of in vivo treatment effect and downstaging
as a potential surrogate for longer term outcomes. One popular
endpoint, pathologic complete response (ypCR) represents the
ultimate degree of tumor downstaging defined as no histo-
pathologic visible residual tumor remaining after neoadjuvant
therapy. This endpoint has been extensively studied in phase
III randomized controlled trials [7••, 8, 9••]. However,
Table 1 Required and optimal parameters for a surrogate endpoint in rectal cancer clinical trials
Required elements Optimal additional elements
Correlates with the true endpoint (individual level association) Surrogate endpoint achieved at or near completion of the experimental intervention
Effect of treatment correlates between surrogate and true endpoint
(trial level association)
High reproducibility across different study designs and interventions
Low/no added cost
Low/no added complexity
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consistent across these studies was the finding that despite
increasing the ypCR, which did correlate with improved local
control, OS was not significantly impacted. Pathologic com-
plete response after neoadjuvant CRT is dependent upon the
inherent chemo-radiosensitivity of the cancer, bulk of the orig-
inal tumor, and interval after completion of CRT. While ypCR
has been suggested to be a valuable trial surrogate, it has not
been endorsed as a validated endpoint in part due to these
limitations [20–22].
Since ypCR represents a binary Ball or nothing^ histopath-
ologic variable, a continuum of treatment regression has been
proposed to represent treatment response as a surrogate for
survival endpoints [23]. Tumor regression grade (TRG) re-
quires standardization, as there are at least four different insti-
tutional or programmatic versions currently in use (Table 2)
[24•, 25•, 26–29]. All versions remain relatively subjective in
pathologic scoring, usually requiring central pathologic re-
view when incorporated into multicenter clinical trials
[30–33]. Early studies involving radiographic imaging modal-
ities (such as MRI, contrast-enhanced cross-sectional imag-
ing, and FDG-PET) demonstrate the potential to serve as sur-
rogates for histopathology, with their own limitations on stan-
dardization, reproducibility, and generalizability [34–39].
While each of these proposed endpoints fulfills some of the
criteria for a surrogate endpoint (Table 1), challenges remain
in validation and widespread reproducibility.
Neoadjuvant Rectal Score
Valentini and colleagues developed a nomogram for predicting
local recurrence, distant metastases, and OS for patients with
locally advanced rectal cancer [40••]. The nomogram for OS
takes into consideration the clinical tumor (cT) stage, pathologic
tumor (pT) stage, pathologic nodal (pN) stage, patient age, ad-
juvant chemotherapy administration, surgery type (APR vs.
LAR), dose of radiotherapy, and gender [40••]. The OS nomo-
gram had a very respectable c-index (0.70) supporting a strong
correlation which was derived from external validation in five
European rectal cancer clinical trials [7••, 8, 41–43].
The NAR score was developed as a short-term clinical trial
surrogate endpoint to take variables associated with treatment
effect beyond ypCR into consideration yet simple enough to
support a diversity of clinical trial designs. The NAR score is
calculated based on data supported by the Valentini nomo-
gram for OS, but only using the clinical T stage and pathologic
T and N stages (Fig. 1). Of the eight variables used in the
Valentini nomogram, only pN and pT are potentially influ-
enced by neoadjuvant therapy. We include cT in the calcula-
tion of the NAR score based on our belief that the degree of
tumor downstaging is more important than the absolute pT.
The remaining factors from the Valentini nomogram (age,
gender, type of surgery, radiation dose, and receipt of adjuvant
therapy) would not be influenced by neoadjuvant therapy and
thus cannot contribute to a useful surrogate endpoint for
assessing neoadjuvant treatment. The NAR formula, impor-
tantly, serves as a pseudo-continuous variable with 24 possible
discrete scores from 0 to 100 with higher scores representing a
poorer prognosis. The formula also standardizes downstaging
by incorporating the treatment effect on the T stage, which
accounts for bulky or large tumors regressing, but not to the
point of ypCR. The relative weights of 5 for pN and 3 for
downstaging of Twere suggested by the Valentini nomogram
and reflect the relative importance of these variables. The
constant 12 assures that all scores are positive inside the
brackets. Squaring the numerator transforms the score to a
more uniform measure per unit change. The scaling factor
9.61 in the denominator ensures that the final scores range
from 0 to 100. The NAR score is meant to be used in clinical
trials as a surrogate endpoint for survival. The score is de-
signed to be particularly sensitive to changes in factors that
are affected by neoadjuvant therapy. Changes in mean NAR
scores between treatment arms as a result of intervention
should translate to changes in OS. Importantly, the score uses
both clinical and pathologic factors that are universally
available in rectal cancer clinical trials, obviating the need
Table 2 Summary of major tumor regression grade systems in use
Score Dworak, et al. (score 0–4) [23] American Joint Committee
on Cancer (score 0–3) [26]
Mandard, et al. (score 1–5) [27] Memorial Sloan
Kettering
CC (score 1–3) [29]
TRG 0 Minimal tumor response to treatment No residual tumor cells – –
TRG 1 Fibrosis in <25 % of tumor Single or small group of cells No residual tumor cells No residual tumor cells
TRG 2 Fibrosis in 25–50 % of tumor Cancer with fibrotic response Rare cancer cells 86–99 % tumor response
TRG 3 Fibrosis in >50 % of tumor Minimal tumor response to treatment Fibrosis>residual cancer ≤85 % tumor response
TRG 4 No residual tumor cells – Residual cancer>fibrosis –
TRG 5 – – Minimal tumor response to treatment –
TRG tumor regression grade
Curr Colorectal Cancer Rep (2015) 11:275–280 277
for additional trial infrastructure, cost, time, or effort. The
score was not designed or intended for individual patient use
or to provide prognosis as part of clinical care. In that regard,
the original Valentini nomogram is better suited for that
purpose.
After establishing the NAR score calculation, it was
validated using the NSABP R-04 clinical trial patient
dataset [44••]. The NSABP R-04 study involved 1479 pa-
tients with stages II or III rectal cancer and randomized
them to one of four neoadjuvant CRT arms testing different
radiosensitizers including (1) continuous infusion 5-fluo-
rouracil, (2) continuous infusion 5-fluorouracil with week-
ly oxaliplatin, (3) oral daily capecitabine, or (4) oral daily
capecitabine plus weekly oxaliplatin. Outcomes were ana-
lyzed in a 2 × 2 factorial design to assess the relative dif-
ferences between infusional 5-FU vs. capecitabine and
oxaliplatin vs. no oxaliplatin [45]. Continuous NAR score
was significantly associated with OS (HR/unit 1.04; 95 %
CI 1.03–1.05; p<0.0001) [44••]. NAR scores in the
NSABP R-04 trial dataset were categorized as low (NAR
<8), intermediate (NAR=8–16), and high (NAR >16)
based on tertiles of the observed scores. These categories
were significantly associated with OS (p<0.0001) with
5 year OS values of 92, 89, and 68 %, respectively
(Fig. 2). OS was also predicted by ypCR in this analysis,
but continuous NAR score had a stronger association as
measured by Akaike’s information criterion (p<0.0001).
The NAR score was subsequently and independently fur-
ther validated in an international clinical trial dataset pro-
viding further evidence of utility as a short-term surrogate
[46].
Conclusions and Future Directions
The NAR score represents the next logical step in defining
a short-term surrogate clinical trial endpoint in rectal can-
cer study design. It is undergoing trial level validation cur-
rently and otherwise meets all the requirements for a sur-
rogate endpoint outlined in Table 1. The NAR score is now
poised to serve as the primary endpoint of upcoming phase
II studies being designed within NRG Oncology and the
NCI National Clinical Trials Network. It has already been
adopted as a secondary endpoint by several ongoing phase
I and II studies testing novel radiosensitizers and other
neoadjuvant interventions in rectal cancer, including the
incorporation of induction chemotherapy or total neoadju-
vant therapy. With the development of this surrogate end-
point and incorporation into rectal cancer clinical trials, we
anticipate more rapid scientific progress to the benefit of
our patients and their families.


















Low Score Reference, p < 0.0001
Int Score HR=1.53 (1.00-2.33)
High Score HR=4.48 (3.03-6.63)
Fig. 2 Overall survival by
neoadjuvant rectal (NAR) score
by group in NSABP R-04 clinical
trial
=
[5 − 3( − ) + 12]
9.61
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Fig. 1 Calculation of the neoadjuvant rectal (NAR) score. cT is an element of the set {1, 2, 3, 4}, pT is in {0, 1, 2, 3, 4}, and pN is in {0, 1, 2}. cT clinical
tumor stage, pT pathologic tumor stage, pN pathologic nodal stage
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